Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 2/3 2Phase NA 1Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Pain, Postoperative 3Neoplasms 2Agnosia 2Thyroid Neoplasms 1Postoperative Analgesia 1Pain, Intractable 1Neoplasm Metastasis 1Inflammation 1

Interventions

Trimethoprim, Sulfamethoxazole Drug Combination 4gamma-Globulins 3Standard of Care 3Oxaliplatin 3Melatonin 3Gemcitabine 3Fluorouracil 3Drug Therapy 3Ciprofloxacin 3Capecitabine 3pertuzumab 2entrectinib 2cobimetinib 2capmatinib 2atezolizumab 2alectinib 2Water 2Vemurafenib 2Trastuzumab 2Sirolimus 2Saline Solution 2Pemetrexed 2Methylphenidate 2Lidocaine 2Leucovorin 2Immunoglobulins, Intravenous 2Docetaxel 2Dexmedetomidine 2Cisplatin 2Carboplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Neoplasms × Dexmedetomidine × Clear all
NCT05636566 2022-12-05

Comparing TIVA Using Propofol or Dexmedetomidine Versus Sevoflurane During Anaesthesia of Children Undergoing Bone-Marrow Aspiration

Alexandria University

Phase 2/3 Completed
60 enrolled
Tumor-Agnostic

Neoplasms

NCT04106999 2022-11-03

Dexmedetomidine and HIPEC

University of British Columbia

Phase 2/3 Unknown
20 enrolled

Inflammation, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡